Sana Biotechnology Inc (SANA)

$2.83 +0.28 (10.98%)
Market Cap 523.11M
Revenue (ttm) 0.00
Net Income (ttm) -266.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,817,300
Avg Vol 3,728,686
Day's Range N/A - N/A
Shares Out 225.48M
Stochastic %K 94%
Beta 1.78
Analysts Strong Sell
Price Target $9.33

Latest News on SANA

Sana Biotechnology to Present at June 2025 Investor Conferences

May 28, 2025, 4:05 PM EDT - 8 days ago

Sana Biotechnology to Present at June 2025 Investor Conferences

Sana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes Treatment

May 19, 2025, 3:10 PM EDT - 18 days ago

Sana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes Treatment

The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants

May 19, 2025, 11:57 AM EDT - 18 days ago

The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology

May 14, 2025, 2:50 PM EDT - 23 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology

Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference

May 12, 2025, 4:05 PM EDT - 24 days ago

Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA

May 8, 2025, 5:45 AM EDT - 4 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology

Apr 19, 2025, 8:10 AM EDT - 6 weeks ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology

Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421

Mar 24, 2025, 11:45 PM EDT - 2 months ago

Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421

Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 17, 2025, 4:05 PM EDT - 2 months ago

Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference

Feb 24, 2025, 4:05 PM EST - 3 months ago

Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference

Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 5 months ago

Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success

Jan 8, 2025, 10:30 AM EST - 5 months ago

Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success

Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why

Jan 8, 2025, 9:27 AM EST - 5 months ago

Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why

This Biotech Stock Just Soared 240%. Why It Can Go Higher.

Jan 8, 2025, 7:25 AM EST - 5 months ago

This Biotech Stock Just Soared 240%. Why It Can Go Higher.

Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Jan 7, 2025, 4:05 PM EST - 5 months ago

Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus

Dec 4, 2024, 3:36 PM EST - 6 months ago

Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus

Sana Biotechnology to Present at December 2024 Investor Conferences

Nov 25, 2024, 4:05 PM EST - 6 months ago

Sana Biotechnology to Present at December 2024 Investor Conferences

Sana Biotechnology: The Story Becomes Murkier

Nov 19, 2024, 5:31 PM EST - 7 months ago

Sana Biotechnology: The Story Becomes Murkier

Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

Nov 8, 2024, 9:00 AM EST - 7 months ago

Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025

Nov 4, 2024, 4:30 PM EST - 7 months ago

Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025